Revisiting tumor angiogenesis: Vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation

Chinese Journal of Cancer

Volumn 35, Issue 2, 2016, Pages

  Qian, Chao Nan ^a   Tan, M H ^b   Yang, Jun Ping ^a   Cao, Yun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Angiogenesis; Vascular endothelial growth factor; Vessel co option; Vessel remodeling; Vessel like structure

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; BLOOD FLOW; BREAST CANCER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NEOPLASM; PERICYTE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR ANGIOGENESIS; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR REMODELING; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84959498451     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.1186/s40880-015-0070-2     Document Type: Review

References (52)

1. McDonald DM, Baluk P. Imaging of angiogenesis in inflamed airways and tumors: newly formed blood vessels are not alike and may be wildly abnormal: Parker B. Francis lecture. Chest. 2005;128(6 Suppl):602S–8S. doi: 10.1378/chest.128.6_suppl.602S-a
2. Qin L, Bromberg-White JL, Qian CN. Opportunities and chal- lenges in tumor angiogenesis research: back and forth between bench and bed. Adv Cancer Res. 2012;113:191–239. doi:10.1016/B978-0-12-394280-7.00006-3
3. Qian CN, Huang D, Wondergem B, Teh BT. Complexity of tumor vascula- ture in clear cell renal cell carcinoma. Cancer. 2009;115(10 Suppl):2282–9. doi:10.1002/cncr.24238
4. Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ, Yang XJ, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have con- trasting prognostic implications. Clin Cancer Res. 2007;13(1):161–9. doi:10.1158/1078-0432.CCR-06-0774
5. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32(12):1095–111. doi:10.1002/phar.1147
6. Stacker SA, Achen MG. The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer. 2013;32(6):297–302. doi:10.5732/cjc.012.10319
7. Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, et al. A systemic review and meta-analysis of randomized trials on the role of tar- geted therapy in the management of advanced gastric cancer: evidence does not translate? Cancer Biol Ther. 2015. doi: 10.1080/15384047.2015.10 56415
8. Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepa- tocellular carcinoma and sorafenib: diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7(8):1041–53. doi:10.4254/wjh.v7.i8.1041
9. Della Pepa C, Tonini G, Pisano C, Di Napoli M, Cecere SC, Tambaro R, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer. 2015;34(1):17–27. doi:10.5732/cjc.014.10274
10. Gadducci A, Lanfredini N, Sergiampietri C. Antiangiogenic agents in gynecological cancer: state of art and perspectives of clinical research. Crit Rev Oncol Hematol. 2015. doi:10.1016/j.critrevonc.2015.05.009
11. Chen YS, Chen ZP. Vasculogenic mimicry: a novel target for glioma therapy. Chin J Cancer. 2014;33(2):74–9. doi:10.5732/cjc.012.10292
12. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987–9. doi:10.1038/nm0901-987
13. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. doi:10.1126/science.1104819
14. von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011;17(19):6192–205. doi:10.1158/1078-0432.CCR-10-1868
15. Qian CN. Hijacking the vasculature in ccRCC—co-option, remodel- ling and angiogenesis. Nat Rev Urol. 2013;10(5):300–4. doi:10.1038/nrurol.2013.26
16. Motiejunaite R, Aranda J, Kazlauskas A. Pericytes prevent regression of endothelial cell tubes by accelerating metabolism of lysophosphatidic acid. Microvasc Res. 2014;93:62–71. doi:10.1016/j.mvr.2014.03.003
17. Schrimpf C, Xin C, Campanholle G, Gill SE, Stallcup W, Lin SL, et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol. 2012;23(5):868–83. doi:10.1681/ASN.2011080851
18. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signal- ing and Bcl-w expression. Blood. 2011;118(10):2906–17. doi: 10.1182/blood-2011-01-331694
19. Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, et al. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol. 2012;137(3):391–401. doi: 10.1007/s00418-011-0898-8
20. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, et al. Bevacizumab-induced normaliza- tion of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013;73(11):3347–55. doi:10.1158/0008-5472.CAN-12-3518
21. Franco M, Paez-Ribes M, Cortez E, Casanovas O, Pietras K. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res. 2011;43(12):884–9. doi:10.1055/s-0031-1284381
22. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA. 2002;99(17):11399–404. doi:10.1073/pnas.172398399
23. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442
24. Farnsworth RH, Lackmann M, Achen MG, Stacker SA. Vascular remodeling in cancer. Oncogene. 2014;33(27):3496–505. doi:10.1038/onc.2013.304
25. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, et al. Preparing the “soil”: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006;66(21):10365–76. doi:10.1158/0008-5472.CAN-06-2977
26. Qian CN, Resau JH, Teh BT. Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle. 2007;6(5):514–7.
27. Sakai Y, Kobayashi M. Lymphocyte ‘homing’ and chronic inflammation. Pathol Int. 2015;65(7):344–54. doi:10.1111/pin.12294
28. Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, et al. Investiga- tion of the lack of angiogenesis in the formation of lymph node metasta- ses. J Natl Cancer Inst. 2015. doi:10.1093/jnci/djv155
29. Lee SY, Chao-Nan Q, Seng OA, Peiyi C, Bernice WH, Swe MS, et al. Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis. J Transl Med. 2012;10:206. doi: 10.1186/1479-5876-10-206
30. Farnsworth RH, Karnezis T, Shayan R, Matsumoto M, Nowell CJ, Achen MG, et al. A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. Cancer Res. 2011;71(20):6547–57. doi:10.1158/0008-5472.CAN-11-0200
31. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000;156(2):361–81. doi:10.1016/ S0002-9440(10)64739-6
32. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. 2012;181(4):1115–25. doi:10.1016/j.ajpath.2012.07.013
33. Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu D, et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med. 2015;19(2):315–26. doi:10.1111/jcmm.12496
34. RicciVitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824–8. doi:10.1038/nature09557
35. Soda Y, Myskiw C, Rommel A, Verma IM. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl). 2013;91(4):439–48. doi:10.1007/s00109-013-1019-z
36. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31:16. doi:10.1186/1756-9966-31-16
37. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate can- cer: a mechanism of radioresistance and treatment failure. Front Oncol. 2015;5:90. doi:10.3389/fonc.2015.00090
38. Jang YY, Sharkis SJ. Stem cell plasticity: a rare cell, not a rare event. Stem Cell Rev. 2005;1(1):45–51. doi:10.1385/SCR:1:1:045
39. Zane M, Scavo E, Catalano V, Bonanno M, Todaro M, De Maria R, et al. Nor- mal vs cancer thyroid stem cells: the road to transformation. Oncogene. 2015. doi:10.1038/onc.2015.138
40. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science. 1992;257(5074):1258–61
41. Cocola C, Sanzone S, Astigiano S, Pelucchi P, Piscitelli E, Vilardo L, et al. A rat mammary gland cancer cell with stem cell properties of self-renewal and multi-lineage differentiation. Cytotechnology. 2008;58(1):25–32. doi:10.1007/s10616-008-9173-9
42. Ruffini F, Graziani G, Levati L, Tentori L, D’Atri S, Lacal PM. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of alphavbeta5 integ- rin. Int J Cancer. 2015;136(6):E545–58. doi:10.1002/ijc.29252
43. Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q, et al. ZEB2 promotes vascu- logenic mimicry by TGF-beta1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Exp Mol Pathol. 2015;98(3):352–9. doi:10.1016/j.yexmp.2015.03.030
44. Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z, et al. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta. 2013;1836(2):273–86. doi:10.1016/j.bbcan.2013.08.001
45. Lirdprapamongkol K, Chiablaem K, Sila-Asna M, Surarit R, Bunyaratvej A, Svasti J. Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2012;422(3):429–35. doi:10.1016/j.bbrc.2012.05.009
46. Liu YR, Sun B, Zhao XL, Gu Q, Liu ZY, Dong XY, et al. Basal caspase-3 activ- ity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res. 2013;23(4):243–53. doi: 10.1097/CMR.0b013e3283625498
47. Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu M, et al. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett. 2014;355(1):148–58. doi:10.1016/j.canlet.2014.09.005
48. Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL, Maceli AR, et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 2015;520(7547):358–62. doi:10.1038/nature14403
49. Maddipati R, Stanger BZ. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 2015. doi: 10.1158/2159-8290.CD-15-0120
50. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71(8):3162–72. doi: 10.1158/0008-5472.CAN-10-3557
51. Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, et al. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyn- geal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis. 2012;33(7):1302–9. doi:10.1093/carcin/bgs181
52. Li XJ, Qian CN. Serglycin in human cancers. Chin J Cancer. 2011;30(9):585–9. doi:10.5732/cjc.011.10314.